| |
Home »
News » 01/06 »
Biogen MS study meets target
Biogen MS study meets target
Date published: 11/01/2006
Biogen and
Fumapharm have
announced their Phase II study into a new multiple sclerosis (MS) drug has
reached its endpoint. The study was designed to evaluate the efficacy and
safety of BG-12, an oral fumarate, in patients with relapsing-remitting MS.
The companies announced that initial results show BG-12 leads to "a
statistically significant reduction" in the total number of
gadolinium-enhancing brain lesions caused by MS after six months of treatment,
as compared with a placebo. Trials took place in at centres in 10 countries
throughout Europe involving around 250 patients.
Fumapharm, based in
Lucerne, Switzerland, has licensed exclusive worldwide rights to develop and
market BG-12 to the US firm Biogen, which specialises in oncology, neurology
and immunology. Multiple sclerosis leads to nerve damage and loss of motor
function in patients as the brain's messages are impeded while travelling
through the body.
© Adfero Ltd
Disclaimer
AllAboutMedicalSales excludes any warranty, express or implied, as to
the quality, accuracy, timeliness, completeness or fitness for a particular
purpose of this briefing. AllAboutMedicalSales will not be liable for any
claims, penalties, losses, damages, costs, or expenses arising from the use of
or inability to use this briefing or from any unauthorised access to or
alteration of the Briefing. AllAboutMedicalSales makes no warranty that the
contents of this briefing are compatible with all computer systems and
browsers.
|
